A Phase I, Randomised, Multi-centre, Open-label Study to Determine the Pharmacokinetics and Tolerability of Cediranib (RECENTIN, AZD2171) Following a Single and Multiple Oral 20mg or 30 mg Doses in Chinese Patients With Advanced Solid Malignancies.

Trial Profile

A Phase I, Randomised, Multi-centre, Open-label Study to Determine the Pharmacokinetics and Tolerability of Cediranib (RECENTIN, AZD2171) Following a Single and Multiple Oral 20mg or 30 mg Doses in Chinese Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2011

At a glance

  • Drugs Cediranib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 17 Jun 2011 Actual end date changed from Nov 2010 to Apr 2011 as reported by ClinicalTrials.gov.
    • 10 Jun 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top